TrianglePUBLICATIONS · 36542826
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Blood
- Publication date
- 2023 Apr 6
- First author
- Abramson JS
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Abramson JS
- type
- Author
- name
- Solomon SR
- type
- Author
- name
- Arnason J
- type
- Author
- name
- Johnston PB
- type
- Author
- name
- Glass B
- type
- Author
- name
- Bachanova V
- type
- Author
- name
- Ibrahimi S
- type
- Author
- name
- Mielke S
- type
- Author
- name
- Mutsaers P
- type
- Author
- name
- Hernandez-Ilizaliturri F
- type
- Author
- name
- Izutsu K
- type
- Author
- name
- Morschhauser F
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Abramson JS
- type
- Author
- name
- Solomon SR
- type
- Author
- name
- Arnason J
- type
- Author
- name
- Johnston PB
- type
- Author
- name
- Glass B
- type
- Author
- name
- Bachanova V
- type
- Author
- name
- Ibrahimi S
- type
- Author
- name
- Mielke S
- type
- Author
- name
- Mutsaers P
- type
- Author
- name
- Hernandez-Ilizaliturri F
- type
- Author
- name
- Izutsu K
- type
- Author
- name
- Morschhauser F
- type
- Author
- bibliography ids
- nci-bib-563f72c5a78ce75d245e73f1
- book metadata
- content sha256
- 7ba7f472687c7cb791c0e518305a93dd28d513e67863a254b1a71f4806cbfe66
- document type
- citation
- dois
- 10.1182/blood.2022018730
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:36542826
- immutable id
- pubmed:36542826@7ba7f472687c7cb791c0e518305a93dd28d513e67863a254b1a71f4806cbfe66
- journal
- abbreviation
- Blood
- issn electronic
- 1528-0020
- issn print
- 0006-4971
- issue
- 14
- name
- Blood
- nlm unique id
- 7603509
- pages
- 1675-1684
- volume
- 141
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 36542826
- provenance
- batch id
- d370e99271168e8a8a13
- provider
- NCBI PubMed ESummary
- record sha256
- f26a666de59c2cce28bfd75b59581a96720af78b5d99a3ad17fa1a005e9274ba
- response sha256
- f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
- retrieved at
- 2026-09-09T23:48:13.005737+00:00
- publication date
- display
- 2023 Apr 6
- precision
- day
- year
- 2023
- publication types
- Randomized Controlled Trial
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Preserved source evidence · Independent clinical review pending · Not medical advice